Sign in →

Test ID DIPGS Diphtheria Toxoid IgG Antibody, Serum

Useful For

Determining a patient's immunological response to diphtheria toxoid vaccination

 

Aids in the evaluation of immunodeficiency

Method Name

Enzyme Immunoassay (EIA)

Reporting Name

Diphtheria Toxoid IgG Ab, S

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL


Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 30 days
  Frozen  30 days

Clinical Information

Diphtheria is an acute, contagious, febrile illness caused by the bacterium Corynebacterium diphtheriae. The disease is classically characterized by a combination of localized inflammation in the upper respiratory tract with the formation of a diphtheric pseudomembrane over the oropharynx, including the tonsils, pharynx, larynx and posterior nasal passages. C diphtheriae produces a potent diphtheria exotoxin that is absorbed systemically and can lead to cardiac failure and paralysis of the diaphragm.

 

The disease is preventable by vaccination with diphtheria toxoid, which stimulates antidiphtheria toxoid antibodies. In the United States, diphtheria toxoid is administered to children as part of the combined diphtheria, tetanus, and acellular pertussis (TDaP) vaccine. A patient's immunological response to diphtheria toxoid vaccination can be determined by measuring antidiphtheria toxoid IgG antibody using this enzyme immunoassay technique. An absence of antibody formation postvaccination may relate to immune deficiency disorders, either congenital or acquired, or iatrogenic due to immunosuppressive drugs.

Reference Values

Vaccinated: Positive (≥0.01 IU/mL)

Unvaccinated: Negative (<0.01 IU/mL)

Reference values apply to all ages.

Interpretation

Results greater than or equal to 0.01 IU/mL suggest a vaccine response.

 

A diphtheria toxoid booster should be considered for patients with antidiphtheria toxoid IgG values between 0.01 and less than 0.1 IU/mL.

Clinical Reference

1. Booy R, Aitken SJ, Taylor S, et al: Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992;339(8792):507-510

2. Maple PA, Efstratiou A, George RC, et al: Diphtheria immunity in UK blood donors. Lancet 1995;345(8955):963-965

3. WHO meeting report: The Control of Diphtheria in Europe. WHO ref:EUR/ICP/EPI/024 1990

4. Diphtheria in the Postepidemic Period, Europe, 2000–2009 Karen S. Wagner, Joanne M. White, Irina Lucenko, David Mercer, Natasha S. Crowcroft, Shona Neal, Androulla Efstratiou, on behalf of the Diphtheria Surveillance Network Emerg Infect Dis. 2012 Feb; 18(2): 217–225. doi: 10.3201/eid1802.110987

Day(s) and Time(s) Performed

Monday through Friday; 9 a.m.

Analytic Time

Same day/1 day

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

86317

LOINC Code Information

Test ID Test Order Name Order LOINC Value
DIPGS Diphtheria Toxoid IgG Ab, S 48654-8

 

Result ID Test Result Name Result LOINC Value
DIPG Diphtheria IgG Ab 45166-6
DEXDP Diphtheria IgG Value 48654-8

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.